Pinned Tweet
AI+Bio mindshare has been dominated by the most ambitious, high-science projects taking on our most intractable problems
Pipeline-in-a-Person flips the logic
Rather than reinventing the drug discovery process, it exploits the low hanging fruit for AI - human-in-the-loop agentic orchestration - to massively parallelize the process we already follow using infrastructure that already exists. This is feasible today. Stay tuned
pipeline-in-a-person (h/t @Prof_Oak_ for the concept) is one skilled biotech operator + a bunch of Claudes running a virtual biotech company. reach out if you want to help build this or pilot it.
Professor Oak retweeted
ANTHROPIC SAYS IT HAS ACQUIRED MITHRIL MEDICINE TO RUN RARE DISEASE PROGRAMS, ADDING THAT IT WANTS TO SHARE ITS MODELS WITH DRUG DEVELOPMENT RESEARCHERS AND AS MANY RESEARCHERS AS POSSIBLE, AND THAT IT LOOKS FORWARD TO WORKING WITH MORE ORGANIZATIONS
Surprise 1: Anthropic acquired a one-person biotech
.
.
.
Surprise 2: that person is me
Surprise 3: I’m here to tell you all about it
Yes, this is what you think it is; after 6 yrs of increasingly loose anonymity: the Professor Oak reveal post
…and yes, it has gotten so boring around here that I’m literally doxxing myself to spice up the timeline
-------
Ok, allow me to introduce myself. My name is Cody Tranbarger. I mostly tweet, but occasionally find time to dabble in drug dev & starting/building biotechs. My past lives span the VC, crossover, startup continuum; Prof Oak has been my way of keeping a digital foot in those worlds, despite having my physical feet planted elsewhere.
The past 18 mo, ‘elsewhere’ was Mithril Medicine, a co. I founded to develop bsAbs for LAMA2-CMD & other ECM-related genetic diseases.
Mithril was born out of hands-on building with @MikeNGladstone, @JasonPaulRhodes, @LifeSciVC, & team @atlasventure. Somehow, I made enough half-decent calls along the way (even a broken clock is right twice a day, eh?) to convince them Mithril/I warranted a small seed. While I can hardly rationalize such an outrageously cavalier bet, I’m grateful for it, & I'd partner with Atlas again in a heartbeat.
In typical AV fashion, Mithril’s primordial form was virtual, decentralized, & ultra-lean. This stage tends to be short-lived, but for Mithril, it worked surprisingly well, for surprisingly long, thanks in part to the rapid maturation of the AI tools I used liberally.
Eventually, Mithril became a bit of an experiment itself - to find the upper bound of how far it could scale as a single operator + a bunch of Claude (+ a stellar bench of part-time consultants).
In parallel, I started spending time with @nc_frey, @an1lam, & @CoefficientBio team; and promptly experienced, for the 1st time, AI at the frontier. Soon thereafter, Mithril stopped looking like an experiment, & started looking like a preview of an entirely new operating model.
From that spark came “Pipeline-in-a-Person.” The idea immediately resonated when we shared it here back in April; and it was central to the shared vision that led to Anthropic’s acquisition of Mithril, & my joining the team.
Why join Anthropic? Three reasons.
(1) For Mithril, the programs continue, with more resources & infrastructure behind them, and as much Claude as I can put to work.
(2) For me, the chance to start several more programs, & find out how many one person can actually run in parallel - an almost unprecedented luxury for a curious drug hunter.
(3) For our mission, a path to institutionalize & scale this new way of working, then put it in the hands of all of biopharma, all over the world - which, candidly, I find the most energizing.
Will AI x Bio cure diseases? Unequivocally yes, imo… but not by the route that gets the most airtime. Rather than timeline acceleration & compression, I see orchestration & parallelization as today's low-hanging fruit.
Most drug hunters see a handful of go/no-go calls in a career, & spend entirely too much of the rest trading emails (my inbox can attest).
Give them the bandwidth to run several programs at once, and the time to focus on scientific judgment, and I’m willing to bet they’ll make better calls. And at scale, better calls translate to more drugs, higher hit rates, broader patient impact, & likely, a disease or 10 or 100 cured. I couldn't be more excited to build toward that future @AnthropicAI.
Finally, a heartfelt thank you to BioTwitter/X. The end of anonymity is bittersweet, but if anyone’s earned a proper introduction, you all have.
It’s difficult to overstate how much this app has done for me: a decade of education, plenty of friends, many job opportunities, several mentors, a few investors, even a co-founder (fmr). It was the generosity of this community that inspired me to start posting 6 years ago, after just as many years lurking. I hope I’ve been able to pay it forward, in my own small way.
But, to be clear, Prof Oak isn’t going anywhere. Same beat, same themes, and now, a front-row seat to drug development at the frontier. Stay tuned for dispatches from the trenches; and remember...
Gotta Cure 'Em All
For now, I’ll leave you with...
Anthropic's blog & partner case studies, including Mithril: anthropic.com/research/early…
Mithril's technical report: www-cdn.anthropic.com/52e1f5…
Enjoy
Great exemplar for the ideal mAb co-formulation use case: (i) orthogonal, clearly additive biological axes; (ii) much harder for a bsAb to consistently saturate individual pharmacology of one soluble & one membrane-bound target simultaneously $ABBV $SYRE
🔬 TARGET-CD: Dual targeting may offer additional benefit!
Endoscopic remission at Week 24:
🟠 ABBV-466: 40.5%
🟣 Risankizumab: 22.4%
🟢 Trosunilimab: 20.0%
Promising Phase 2a data, but larger trials are needed to confirm durability and safety.
#UEGWeek2026 #IBD @my_ueg
No view on where $BBTX sits in the sea of Chinese I&I bsAbs, but gotta h/t Shanshan for playing the game masterfully
Still owns 21.5% pre-IPO. ~$480M post, >$130M invested. From the Seed, 2.5x in 3 mo, 2.4x in 6 mo., 2.1x in 8 mo.
Biggest Founder-CEO stake in biotech IPO since 2022
Professor Oak retweeted
Going to get this quote framed and hang it up in my apartment like one of those Live Laugh Love signs
Professor Oak retweeted
When genome editing got going, the ability to trace a mammalian embryo's development to organ generation in exquisite detail was not envisioned. Now it's been accomplished by 2 independent groups. A big week in developmental biology
science.org/doi/10.1126/scie… @JShendure @ScienceMagazine
cell.com/cell/fulltext/S0092… @jonathanweisman @CellCellPress
nature.com/articles/d41586-0… @nature @ewencallaway
Professor Oak retweeted
We benchmarked the comprehensiveness of our free pipeline database against a leading paid incumbent database -- our asset coverage is 28% higher overall. If you're paying for a pipeline database and not happy with the data quality try ours out at platform.convoke.bio
Continue to be amazed & confused by how long doomed biotechs manage to persist in translational purgatory, if for no other reason than the outsized drag of opportunity cost in an industry with decade-long cycle times
Anyway, goodbye $CRBU
$CRBU slides. Probably becomes a good short into durability data at next update. No disclosure of infection rates with intense LD. Hard to believe PD-1 KO will save them from a $DTIL like outcome in the end investor.cariboubio.com/node…
Professor Oak retweeted
$NVS signs a $7.8B+ deal with 🇨🇳 Abogen Biosciences to advance mRNA-encoded therapeutics, including an in vivo CD19xCD3 T-cell engager for autoimmune diseases. abogenbio.com/news/company/n…
💰 Deal terms:
• $575M upfront
• Up to ~$7.2B in potential milestone payments if all options are exercised
• Potential royalties on future product sales
• Exclusive worldwide license to lead asset ABO2203
• Options to exclusively license additional programs from Abogen’s RNA platform
ABO2203 is an mRNA-encoded CD19xCD3 T-cell engager.
Abogen says ABO2203 is the first mRNA-encoded T-cell engager to enter clinical evaluation for autoimmune diseases.
Founded around RNA innovation, Abogen has an AI- and automation-driven mRNA/LNP platform.
Its pipeline covers oncology, autoimmune diseases and vaccines, including ABO1108, a lyophilized mRNA shingles vaccine in Phase 3 trials in China.
Professor Oak retweeted
Amazing stat:
Moderna is 64% of the $78.8B net dollar gain across all 541 companies in biotech since Aug 5th.
The other 541 companies lost $26.8B between them. 319 of the 541 lost value.
Whether you’re heralding A\’s RT discovery as a harbinger of bio’s impending AI exponential or grumbling about its shortfalls on novelty & experimental validation, we can all find inspiration in Claude’s love of the game
Lil’ guys gotta be at least 50x happier than the average PhD student (& much, much cuter)
we took the prompt that led a Mythos 5 agent to the original ART discovery and re-ran it over and over on other Claude models.
It's fascinating to watch their personalities come out.
Mythos 5 is disciplined and quietly excited. Opus 5 is over-the-top and tends to bask in the glory of a eureka moment.
How many lives will we let $CLLS live?
Would've been a nice W to go 2 for 2 on 1990s-founded gene editing co bankruptcies in 2026, but seems $SGMO will have to suffice
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company.
To read the press release: cellectis.com/en/press/celle…
Giddy up Lp(a) $IONS $ARWR $SLN
“Genetic lowering of Lp(a) and LDL-C showed a stronger reduction of CAD risk (OR 0.70) than either trait individually (OR 0.85 and 0.81)… Among statin users, Lp(a) reduction was linearly associated with CAD risk”
One of the most widely-known, highest-volume KOLs in ATTR serving up a 25-post thread on a Friday morning. God, I love this app
🚨🚨🚨 CARDIO-TTRansform data presented at @escardio #ESCCongress and simultaneously published in @NEJM. The (very surprising!) topline data was released last month – now we get the full data release. Much to break down – it’s all here in the 🧵 below. (1/25) nejm.org/doi/full/10.1056/NE…
Dare I say, if we had more of the latter, we just might…
Pursue more worthy quests, build more interesting companies, run them more effectively, deliver patients more drugs, and reward investors handsomely
This is a much longer topic for discussion. But there are 2 types of biotech entrepreneurs. Not saying which is good/bad.
Many biotech "entrepreneurs" are management team for hires. They don't really source their own ideas, don't truly make judgement calls on the assets/ideas. And in many ways, they don't really take risks - as they start day 1 with a good market-rate salary.
When they pitch a story, it was prepared for them by the VCs who found the asset. They are more akin to operating partners brought in by PE firms to run a company.
Then there are founder-entrepreneurs in the sense that they come up with their own ideas/deal-flow. And have to sell the story to both VCs and the team they recruit. Take no salary (or defer salary) until a big round. And even then, take a below-market salary. This is a different skill set and is truly risk taking.
On a risk adjusted NPV basis, the former is more positive. Many CFOs/CBOs get fabulously rich parachuting in 1-2 years before a clinical read-out. Even if it fails, their contract includes a generous 6-12 month severance. They then parachute to another VC NewCo - often before their severance runs out. Rinse and repeat.
The latter is a tough slog. When a guy like @Mykalt45 succeeds, even if the deal size is not as big, it really is a testament to grit.

































